Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPLAND: Dacomitinib and Osimertinib Sequencing in EGFR+ NSCLC
NCT04811001Phase 2Unknown
- Sponsor
- Fondazione Ricerca Traslazionale
- Start
- Jun 2020
- Primary completion
- Dec 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dacomitinib in non-small cell lung cancer (NSCLC), sponsored by Fondazione Ricerca Traslazionale. Primary endpoint: Overall Survival up to 2 years. Status: unknown.
02
Drugs
dacomitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04811001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04811001.